Department of Endocrinology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.
Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, China.
Clin Ther. 2020 Aug;42(8):1549-1563. doi: 10.1016/j.clinthera.2020.06.006. Epub 2020 Aug 8.
Patients with diabetes and health care professionals (HCPs) play important roles in effective application of injectable antidiabetic therapies (IATs). However, their concerns and opinions on IATs are rarely investigated in China. This study aims to assess unmet medical needs of IATs regarding patient concerns, patient satisfaction, aspects that need improvement, and training burden from patient and HCP perspectives.
This cross-sectional survey was conducted in 12 representative Chinese cities from December 2018 to January 2019. Patients with adult type 2 diabetes who were receiving IAT currently and had received IAT continuously for at least 1 month before the survey, endocrinologists with ≥5 years of experience and prescribing IAT in the past 1 month, and nurses with ≥3 years of experience and providing IAT training in the past 1 month were eligible participants. The patient survey assessed concerns of initiating IAT, satisfaction with IAT, aspects of IAT that need improvement, and IAT training received. The HCP survey evaluated patient concern of initiating IAT, aspects of IAT that need improvement, experience of providing IAT training, and self-reported burden of training. Descriptive statistical analysis was performed.
In total, 500 patients, 200 endocrinologists, and 100 nurses were surveyed. The mean (SD) age of patients was 55.1 (11.8) years, with a disease duration of 7.6 (6.4) years. Of all patients, 391 (78.2%) were insulin users and 109 (21.8%) were glucagon-like peptide 1 receptor agonist users. Of the top 4 concerns about initiating IAT, both patients and endocrinologists reported inconvenience of daily injection (58.0% of patients and 68.5% of endocrinologists), worries about insulin dependence (42.6% of patients and 62.5% of endocrinologists), and fear of injection (37.0% of patients and 66.5% of endocrinologists). Medical expenses, convenience of drug portability and storage, and injection site reactions were the top 3 aspects that need improvement according to both patients and HCPs. High injection frequency was also one of the most urgent aspects for improvement (mean urgency score, 3.8 for physicians and 4.0 for nurses). A typical IAT training session took a mean (SD) of 14.1 (9.7) minutes. Both patients and HCPs considered injection operation after dose is set and symptoms and treatment for adverse effects as the 2 most time-consuming training contents. In addition, 97.1% of endocrinologists who provided training and 97.0% of nurses thought a more user-friendly IAT would reduce their training burden.
Study results indicate that the IATs with more convenient drug portability and storage, fewer injection site reactions and adverse events, less injection frequency, more user-friendly design, and fewer steps for injection might help improve patient experience with self-injection and reduce HCPs' training burden.
糖尿病患者和医疗保健专业人员(HCPs)在有效应用注射用抗糖尿病疗法(IATs)方面发挥着重要作用。然而,中国很少调查他们对 IATs 的关注和意见。本研究旨在从患者和 HCP 的角度评估 IATs 未满足的医疗需求,包括患者关注、患者满意度、需要改进的方面和培训负担。
本横断面调查于 2018 年 12 月至 2019 年 1 月在中国 12 个有代表性的城市进行。正在接受 IAT 治疗且在调查前至少连续接受 IAT 治疗 1 个月的成年 2 型糖尿病患者、过去 1 个月内有≥5 年经验且开具 IAT 处方的内分泌医生、以及过去 1 个月内有≥3 年经验且提供 IAT 培训的护士均有资格参加。患者调查评估了开始使用 IAT 的顾虑、对 IAT 的满意度、IAT 需要改进的方面以及接受的 IAT 培训。HCP 调查评估了开始使用 IAT 的患者顾虑、IAT 需要改进的方面、提供 IAT 培训的经验以及自我报告的培训负担。进行了描述性统计分析。
共调查了 500 名患者、200 名内分泌医生和 100 名护士。患者的平均(SD)年龄为 55.1(11.8)岁,病程为 7.6(6.4)年。所有患者中,391 名(78.2%)为胰岛素使用者,109 名(21.8%)为胰高血糖素样肽 1 受体激动剂使用者。在开始使用 IAT 的前 4 大顾虑中,患者和内分泌医生都报告日常注射不便(58.0%的患者和 68.5%的内分泌医生)、担心胰岛素依赖(42.6%的患者和 62.5%的内分泌医生)和害怕注射(37.0%的患者和 66.5%的内分泌医生)。根据患者和 HCPs 的报告,医疗费用、药物便携性和存储便利性以及注射部位反应是需要改进的前 3 大方面。高注射频率也是最需要改进的方面之一(医生的平均紧迫性评分 3.8,护士的平均紧迫性评分 4.0)。典型的 IAT 培训课程平均(SD)需要 14.1(9.7)分钟。患者和 HCPs 都认为剂量设置后的注射操作和不良反应的症状及治疗是最耗时的 2 项培训内容。此外,97.1%提供培训的内分泌医生和 97.0%的护士认为更便于患者使用的 IAT 会减轻他们的培训负担。
研究结果表明,具有更方便的药物便携性和存储性、更少的注射部位反应和不良反应、更低的注射频率、更便于患者使用的设计以及更少的注射步骤的 IAT 可能有助于改善患者的自我注射体验,并减轻 HCP 的培训负担。